Tetramethoxyluteolin — Safety, Research, Risks & Legal Status

Not medical advice. Tetramethoxyluteolin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	3',4',5,7-tetramethoxyluteolin; 5,7,3',4'-tetramethoxyflavone; luteolin tetramethyl ether; methlut; CAS 855-97-0
Category	Supplement
CAS Number	855-97-0
Molecular Formula	C19H18O6 (MW 342.35 g/mol)
Drug Class	Polymethoxyflavone; synthetic tetramethyl ether of luteolin
Commercial Product	GentleDerm lotion (topical; Algonot brand; combined with olive fruit extract)
Registered Clinical Trials	Zero as of 2025 (ClinicalTrials.gov)
Human Evidence Base	Two open-label tolerability studies, topical use only, n=33 total, no placebo control
US legal status	Not FDA-approved as a drug. Marketed in the US as a dietary supplement ingredient and cosmetic/topical product component (GentleDerm lotion). Raw compound is available from chemical suppliers for research use. No DEA scheduling or controlled substance classification. No registered clinical trials on ClinicalTrials.gov as of 2025.

What is Tetramethoxyluteolin?

Tetramethoxyluteolin is a synthetic polymethoxyflavone — the tetramethyl ether derivative of the naturally occurring flavone luteolin. The four methoxy substitutions at positions 5, 7, 3', and 4' increase lipophilicity relative to the parent compound, which is proposed to enhance cellular membrane penetration and reduce first-pass hepatic metabolism. It has been studied primarily as a mast cell inhibitor in preclinical and very limited human tolerability settings, and has been commercially formulated into a topical cosmetic lotion (GentleDerm). It is not an approved drug and has no completed controlled clinical trials.

How it works

Tetramethoxyluteolin inhibits mast cell activation through at least two intracellular pathways documented in vitro. First, it blocks the elevation of intracellular calcium that follows mast cell stimulation, dampening degranulation. Second, it suppresses NF-κB pathway activation — specifically phosphorylation of IκBα and nuclear translocation/DNA-binding of the p65 subunit — reducing transcription of pro-inflammatory mediators including TNF-α and CCL2. In neuroinflammation models, it has been proposed to inhibit mast cell and microglial activation mediated by IL-33/CRH signaling. The increased lipophilicity compared to luteolin is mechanistically relevant: greater membrane permeability may underlie the superior potency observed in cell-based assays relative to the parent compound.

Background & history

Research on tetramethoxyluteolin as a distinct pharmacological agent was developed primarily by Dr. Theoharis C. Theoharides at Tufts University School of Medicine, a laboratory with a long focus on mast cell biology and neuroinflammation. Key in vitro characterization was published in the Journal of Allergy and Clinical Immunology in 2014-2015, demonstrating potent mast cell inhibition in human LAD2 cells and cord-blood derived mast cells. Limited open-label tolerability data for a topical formulation (GentleDerm lotion, combining tetramethoxyluteolin with olive fruit extract) appeared around 2017. The compound is manufactured under an exclusive agreement between BiomedAdvice, LLC and Skyherb Technologies Co., Ltd. (Hangzhou, China), and is sold commercially under the Algonot brand. Proposed applications for neuroinflammatory and neurodegenerative conditions — including theoretical intranasal delivery for autism spectrum disorder, fibromyalgia, and ME/CFS — have been described in review articles but have not advanced to registered clinical trials as of 2025.

What the research says

Human clinical evidence is minimal. Two small, open-label, uncontrolled tolerability studies of a tetramethoxyluteolin-containing skin lotion (GentleDerm) have been published — one with n=25 and one with n=8 participants — totaling 33 individuals assessed over 1-6 weeks. Neither study included a placebo arm or active comparator, and neither was designed to demonstrate efficacy. No adverse events were reported in either study. In vitro evidence in human mast cell lines is comparatively robust, with JACI-published data confirming potent inhibition of mast cell mediator release at low micromolar concentrations. A passive cutaneous anaphylaxis mouse model provides limited in vivo support. The neuroinflammation and neurodegenerative disease use case (intranasal delivery, autism, ME/CFS, fibromyalgia) rests entirely on theoretical frameworks and mechanistic extrapolation from mast cell biology — no clinical trials in these populations have been registered or reported. ClinicalTrials.gov shows zero registered trials for this compound.

Reported effects

Inhibition of mast cell degranulation and mediator release (in vitro, human cell lines)
Suppression of TNF-α and CCL2 expression via NF-κB pathway blockade (in vitro)
Reduction of intracellular calcium elevation following mast cell stimulation (in vitro)
Improved cellular uptake relative to parent compound luteolin due to enhanced lipophilicity (in vitro)
Proposed inhibition of neuroinflammatory signaling via IL-33/CRH pathway (preclinical/theoretical)
Topical tolerability observed in 33 subjects without reported adverse events (open-label, uncontrolled)
Proposed applications in neuroinflammatory conditions remain unvalidated in clinical trials

Dosing & administration (informational)

Published literature describes topical application of a lotion formulation in two small open-label studies; systemic or oral dose ranges used in humans have not been reported in peer-reviewed literature. Preclinical cell-based assays used concentrations in the low micromolar range, which do not translate directly to human doses. Proposed intranasal formulations discussed in theoretical review articles have not been tested in humans. No dose-finding, pharmacokinetic, or dose-response clinical studies have been conducted. This information is provided for reference purposes only and does not constitute dosing guidance. Consult a qualified clinician before any use.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No adverse events reported in published human studies (n=33 topical users, 1-6 weeks); evidence base is narrow and uncontrolled
In vitro cell viability exceeds 98% at 100 μM; no ATP depletion observed in mast cell lines
Systemic bioavailability, oral pharmacokinetics, and long-term safety have not been characterized in humans
Intranasal delivery route proposed in theoretical literature has no documented human safety or tolerability data
No controlled safety pharmacology studies published; drug-drug interaction profile is unknown
Related polymethoxyflavones (e.g., quercetin, luteolin) are generally regarded as safe at dietary levels, but this does not extend to concentrated supplemental or investigational doses of tetramethoxyluteolin
Manufactured in China under contract; third-party testing and quality control consistency cannot be independently verified from published literature

Drug & supplement interactions

Who should avoid it

Using this compound as a substitute for evaluated medical treatments for any neuroinflammatory or neurodegenerative condition
Assuming tolerability data from topical studies (n=33) extends to oral or intranasal routes
Inferring clinical efficacy from in vitro mast cell inhibition data
Purchasing bulk raw compound without verified certificate of analysis and HPLC confirmation of identity
Combining with immunosuppressive drugs without medical supervision given theoretical immunomodulatory activity

How it is commonly combined

No stacking or combination data exists in clinical literature. The commercial GentleDerm formulation combines tetramethoxyluteolin with olive fruit extract in a topical lotion; this combination has not been studied for synergistic or antagonistic effects in a controlled setting. No evidence supports combination use with other mast cell stabilizers, antihistamines, or anti-inflammatory compounds from a human clinical standpoint.

Legal & regulatory. Not FDA-approved as a drug. Marketed in the US as a dietary supplement ingredient and cosmetic/topical product component (GentleDerm lotion). Raw compound is available from chemical suppliers for research use. No DEA scheduling or controlled substance classification. No registered clinical trials on ClinicalTrials.gov as of 2025.

Quality & harm reduction

N
o
i
n
d
e
p
e
n
d
e
n
t
q
u
a
l
i
t
y
o
r
p
u
r
i
t
y
v
e
r
i
f
i
c
a
t
i
o
n
d
a
t
a
i
s
p
u
b
l
i
c
l
y
a
v
a
i
l
a
b
l
e
b
e
y
o
n
d
t
h
e
m
a
n
u
f
a
c
t
u
r
e
r
'
s
s
u
p
p
l
y
c
h
a
i
n
d
e
s
c
r
i
p
t
i
o
n
.
T
h
e
a
c
t
i
v
e
i
n
g
r
e
d
i
e
n
t
i
s
s
o
u
r
c
e
d
f
r
o
m
S
k
y
h
e
r
b
T
e
c
h
n
o
l
o
g
i
e
s
C
o
.
,
L
t
d
.
(
H
a
n
g
z
h
o
u
,
C
h
i
n
a
)
u
n
d
e
r
a
n
e
x
c
l
u
s
i
v
e
a
g
r
e
e
m
e
n
t
w
i
t
h
B
i
o
m
e
d
A
d
v
i
c
e
,
L
L
C
.
P
u
b
l
i
s
h
e
d
r
e
s
e
a
r
c
h
s
t
u
d
i
e
s
u
s
e
d
c
h
a
r
a
c
t
e
r
i
z
e
d
m
a
t
e
r
i
a
l
,
b
u
t
r
e
t
a
i
l
s
u
p
p
l
e
m
e
n
t
p
r
o
d
u
c
t
s
a
r
e
n
o
t
s
u
b
j
e
c
t
t
o
F
D
A
p
r
e
-
m
a
r
k
e
t
p
o
t
e
n
c
y
o
r
p
u
r
i
t
y
a
p
p
r
o
v
a
l
.
C
o
n
s
u
m
e
r
s
a
n
d
r
e
s
e
a
r
c
h
e
r
s
s
h
o
u
l
d
s
e
e
k
c
e
r
t
i
f
i
c
a
t
e
s
o
f
a
n
a
l
y
s
i
s
f
r
o
m
s
u
p
p
l
i
e
r
s
a
n
d
n
o
t
e
t
h
a
t
p
o
l
y
m
e
t
h
o
x
y
f
l
a
v
o
n
e
i
d
e
n
t
i
t
y
a
n
d
q
u
a
n
t
i
f
i
c
a
t
i
o
n
r
e
q
u
i
r
e
H
P
L
C
v
e
r
i
f
i
c
a
t
i
o
n
.

Safer, legal alternative we recommend

Liver Let Live. For liver and metabolic support, our Liver Support formula is a legal supplement option covering a similar goal.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is tetramethoxyluteolin FDA-approved?

No. It is not approved as a drug for any indication. It is marketed as a dietary supplement ingredient and cosmetic topical lotion component. No IND application or drug development program has been publicly documented.

What is the difference between tetramethoxyluteolin and luteolin?

Luteolin is a naturally occurring flavone with free hydroxyl groups at positions 5, 7, 3', and 4'. Tetramethoxyluteolin replaces those four hydroxyl groups with methoxy groups, which increases the molecule's lipophilicity. This structural change is proposed to improve membrane penetration and reduce rapid hepatic metabolism, potentially enhancing intracellular activity relative to luteolin at equivalent concentrations in cell-based models. Whether this translates to meaningful clinical differences in humans is unknown.

Has tetramethoxyluteolin been tested in clinical trials?

No registered clinical trials exist as of 2025. The only published human data consists of two small open-label tolerability studies of a topical lotion formulation (n=25 and n=8), neither of which included a placebo group or was designed to assess efficacy. Proposed uses for neuroinflammatory conditions such as autism spectrum disorder, ME/CFS, and fibromyalgia are theoretical and have not been investigated in controlled human trials.

What dose should I take?

No safe or effective oral or systemic dose for tetramethoxyluteolin has been established in humans. Published studies cover only topical application. This reference does not provide dosing guidance. Consult a qualified clinician before considering any use.

Is tetramethoxyluteolin safe?

The published safety data is very limited: 33 people applied a topical lotion for 1-6 weeks without reported adverse events. Systemic safety — including oral bioavailability, hepatic metabolism, potential toxicity, and long-term effects — has not been characterized in humans. The absence of reported adverse events in a small, short-duration, topical study cannot be interpreted as a general safety endorsement.

Who developed tetramethoxyluteolin and what conditions is it proposed for?

The primary research has come from Dr. Theoharis C. Theoharides at Tufts University School of Medicine, who has focused on mast cell and neuroinflammation biology. Proposed applications include skin inflammatory conditions (existing topical product), and theoretical neuroinflammatory conditions such as autism spectrum disorder, fibromyalgia, and ME/CFS via proposed intranasal delivery. These neurological applications remain entirely theoretical with no clinical trial data.

References & further reading

PubMed: tetramethoxyluteolin mast cell inhibitor Theoharides JACI 2015 (PMID 25498791)
PubMed Central: PMC4388775 tetramethoxyluteolin mast cell mechanism full text
PubMed Central: PMC5806797 tolerability benefit tetramethoxyluteolin skin lotion 2017 open-label
PubMed: tetramethoxyluteolin neurodegenerative diseases Theoharides Tsilioni Current Topics Medicinal Chemistry 2018
ClinicalTrials.gov: tetramethoxyluteolin (zero registered trials as of 2025)